147 related articles for article (PubMed ID: 30747828)
1. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
Kim SJ; Kim MJ; Han JS; Sung YN; An S; Lee JH; Song KB; Hwang DW; Lee SS; Cho H; Kim SC; Eshleman JR; Hong SM
Pancreas; 2019 Mar; 48(3):400-411. PubMed ID: 30747828
[TBL] [Abstract][Full Text] [Related]
2. Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.
Turrini O; Gilabert M; Ewald J; Moutardier V; Delpero JR; Iovanna JL
J Visc Surg; 2017 Oct; 154(5):329-333. PubMed ID: 28844705
[TBL] [Abstract][Full Text] [Related]
3. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
5. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes.
Takahashi D; Kojima M; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nagino M
Pancreas; 2018 Aug; 47(7):830-836. PubMed ID: 29975353
[TBL] [Abstract][Full Text] [Related]
6. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
[TBL] [Abstract][Full Text] [Related]
7. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
8. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
10. Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center.
van Roessel S; Kasumova GG; Tabatabaie O; Ng SC; van Rijssen LB; Verheij J; Najarian RM; van Gulik TM; Besselink MG; Busch OR; Tseng JF
Ann Surg Oncol; 2018 Jun; 25(6):1760-1767. PubMed ID: 29651577
[TBL] [Abstract][Full Text] [Related]
11. Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal adenocarcinoma.
Katou S; Wenning AS; Aeschbacher P; Morgul H; Becker F; Pascher A; Gloor B; Strücker B; Andreou A
Surgery; 2023 Jul; 174(1):91-99. PubMed ID: 37121858
[TBL] [Abstract][Full Text] [Related]
12. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
[TBL] [Abstract][Full Text] [Related]
13. Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma.
Markov P; Satoi S; Kon M
J Hepatobiliary Pancreat Sci; 2016 Sep; 23(9):523-32. PubMed ID: 27524388
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
15. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
[TBL] [Abstract][Full Text] [Related]
19. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
20. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.
Rau BM; Moritz K; Schuschan S; Alsfasser G; Prall F; Klar E
Surgery; 2012 Sep; 152(3 Suppl 1):S103-11. PubMed ID: 22766366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
